Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m.

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

An elderly American man has become completely blind after he was prescribed to take Ozempic to manage his type 2 diabetes. Sixty-two-year-old Todd Engel has sued the manufacturer Novo Nordisk for ...

Lawyers for Todd Engel, 62, filed suit yesterday in New Jersey superior court. According to the complaint, Engel is now ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...